![]() |
|
|
Vol. 299, Issue 1, 187-197, October 2001
Department of Antibacterials, Immunology, and Inflammation, Pfizer Global Research and Development, Pfizer, Inc., Groton, Connecticut
| |
Abstract |
|---|
|
|
|---|
Lipopolysaccharide (LPS)-activated monocytes and macrophages
produce large quantities of pro-interleukin (IL)-1
but externalize little mature cytokine. Efficient post-translational processing of the
procytokine occurs in vitro when these cells encounter a secretion
stimulus such as ATP, cytolytic T cells, or hypotonic stress. Each of
these stimuli promotes rapid conversion of 31-kDa pro-IL-1
to its
mature 17-kDa species and release of the 17-kDa cytokine. In this
study, two novel pharmacological agents, CP-424,174 and CP-412,245, are
identified as potent inhibitors of stimulus-coupled IL-1
post-translational processing. These agents, both diarylsulfonylureas, block formation of mature IL-1
without increasing the amount of
procytokine that is released extracellularly, and they inhibit independently of the secretion stimulus used. Conditioned medium derived from LPS-activated/ATP-treated human monocytes maintained in
the absence and presence of CP-424,174 contained comparable quantities
of IL-6, tumor necrosis factor-
(TNF
), and IL-1RA, but 30-fold
less IL-1
was generated in the test agent's presence. As a result
of this decrease, monocyte conditioned medium prepared in the presence
of CP-424,174 demonstrated a greatly diminished capacity to promote an
IL-1-dependent response (induction of serum amyloid A synthesis by
Hep3B cells). Oral administration of CP-424,174 to mice resulted in
inhibition of IL-1 in the absence of an effect on IL-6 and TNF
.
These novel agents, therefore, act as selective cytokine release
inhibitors and define a new therapeutic approach for controlling IL-1
production in inflammatory diseases.
| |
Introduction |
|---|
|
|
|---|
Interleukin (IL)-1 is a
multipotential proinflammatory cytokine produced in abundance by
activated monocytes and macrophages. Biological activity attributed to
this cytokine is derived from two distinct polypeptides, IL-1
and
IL-1
, that share <30% sequence identity (Dinarello, 1998
). Despite
their low sequence homology, both IL-1
and IL-1
bind to the same
receptors on target cells and elicit comparable responses (Sims and
Dower, 1994
). Relative quantities of the two cytokine species produced
in response to an activation stimulus are cell-dependent. For example,
human monocytes produce large quantities of IL-1
in response to LPS challenge but little IL-1
(Demczuk et al., 1987
). On the other hand,
LPS-activated mouse peritoneal macrophages generate large quantities of
both IL-1
and IL-1
(Perregaux and Gabel, 1998a
). Molecular
mechanisms that govern expression of the two cytokine species are not
well understood.
Cells that produce IL-1 also closely regulate its post-translational
processing. Both forms of IL-1 are synthesized as procytokines containing amino terminal propeptide extensions (Hazuda et al., 1991
).
In the case of pro-IL-1
, removal of the propeptide segment is
necessary for biological activity; in contrast, pro-IL-1
is competent to bind to IL-1 receptors (Mosley et al., 1987
; Hazuda et
al., 1991
). Proteolytic activation of pro-IL-1
is facilitated by
caspase-1, the founding member of a family of cytoplasmically disposed
cysteine proteases involved in apoptotic processes (Cerretti et al.,
1992
; Thornberry et al., 1992
). Importantly, macrophages isolated from
mice engineered to lack caspase-1 are impaired in the generation of
mature, active IL-1
(Kuida et al., 1995
; Li et al., 1995
). Likewise,
inhibitors of caspase-1 prevent proteolytic activation of pro-IL-1
,
and these agents suppress inflammatory processes in vivo (Thornberry et
al., 1992
; Miller et al., 1995
; Ku et al., 1996
). Caspase-1 also is
required for proteolytic activation of pro-IL-18 (Yong et al., 1997
).
Pro-IL-1
, on the other hand, can be cleaved to a 17-kDa mature
species, but this processing proceeds independently of caspase-1
(Carruth et al., 1991
).
Unlike most secreted cytokines, which are synthesized in the rough
endoplasmic reticulum and processed in the Golgi apparatus during their
transport to the cell surface, IL-1 (both
and
) appears to be
synthesized on free polysomes within the cytosol. This atypical
localization results from the absence of signal peptides on the
precursor polypeptides that are required for entry into the endoplasmic
reticulum (Rubartelli et al., 1990
). Caspase-1 also is produced
as an inactive precursor and appears to coexist with pro-IL-1 within
the cytosolic compartment of LPS-activated monocytes (Ayala et al.,
1994
; Miossec et al., 1996
). Mechanisms controlling caspase-1
activation and, in turn, proteolytic cleavage of pro-IL-1
remain to
be delineated. Stimuli that initiate synthesis of pro-IL-1
are not
necessarily sufficient to promote IL-1 post-translational processing.
Thus, LPS promotes synthesis of large quantities of pro-IL-1
in both
monocytes and macrophages, but few of the newly synthesized
polypeptides are externalized as mature active molecules (Hogquist et
al., 1991a
; Chin and Kostura, 1993
; Perregaux et al., 1994
). Efficient
post-translational processing requires that LPS-activated cells
encounter a secondary stimulus such as ATP (Hogquist et al., 1991b
;
Perregaux and Gabel, 1994
), nigericin (Perregaux and Gabel, 1994
),
cytolytic T cells (Hogquist et al., 1991b
), or bacterial toxins (Walev
et al., 1996
). All of these secondary effectors promote major changes
to the ionic composition of the IL-1-producing cell, and these changes
appear necessary for cytokine post-translational processing (Perregaux
and Gabel, 1994
; Walev et al., 1995
; Perregaux et al., 1996
). Moreover,
the aforementioned secretion stimuli promote cell death, suggesting that formation and release of active IL-1 represent terminal cellular processes (Hogquist et al., 1991b
; Perregaux and Gabel, 1994
). Ultimate
sacrifice of the cytokine-producing cell may ensure that a mediator
with the potency and scope of IL-1 is externalized only under
situations of great stress to an organism.
In this study we identify a novel series of agents that inhibit
stimulus-coupled IL-1 post-translational processing. These agents act
independently of the type of stimulus used to activate monocytes and
macrophages, and they arrest the cytokine-producing cell such that
pro-IL-1
is neither cleaved to its mature species nor released
extracellularly. As a result of this arrest, conditioned medium derived
from LPS-activated human monocytes is greatly attenuated in terms of
its ability to generate an IL-1-dependent signaling response after
application to target cells. The effectiveness of these novel agents at
suppressing IL-1 post-translational processing and a monocyte's
signaling capacity demonstrate that control of IL-1 production in
inflammatory disorders such as rheumatoid arthritis may be achieved
with the use of cytokine release inhibitory drugs (CRIDs).
| |
Materials and Methods |
|---|
|
|
|---|
Human Monocyte Isolation.
Blood collected from normal
volunteers in the presence of heparin was fractionated using lymphocyte
separation medium obtained from Organon Technica (Westchester, PA). The
region of the resulting gradient containing banded mononuclear cells
was harvested, diluted with 10 ml of maintenance medium (RPMI 1640, 5%
FBS, 25 mM HEPES, pH 7.2, 1% penicillin/streptomycin), and cells were
collected by centrifugation. The resulting cell pellet was suspended in 10 ml of maintenance medium and a cell count was performed. In an
average metabolic experiment, 1 × 107
mononuclear cells were added to each well of six-well multidishes in a
total volume of 2 ml of maintenance medium. Alternatively, in
experiments where IL-1
production was measured by ELISA, 2 × 105 mononuclear cells were seeded into each well
of 96-well plates in a total volume of 0.1 ml. Monocytes were allowed
to adhere for 2 h, after which the supernatants were discarded and
the attached cells were rinsed twice and then incubated in maintenance
medium overnight at 37°C in a 5% CO2 environment.
ATP-Induced IL-1
Post-Translational Processing.
In the
ELISA format, cultured monocytes in 96-well plates were activated with
10 ng/ml LPS (Escherichia coli serotype 055:B5; Sigma, St.
Louis, MO). After a 2-h incubation, the activation medium was removed,
the cells were rinsed twice with 0.1 ml of chase medium (RPMI 1640, 1%
FBS, 20 mM HEPES, 5 mM NaHCO3, pH 6.9), and then
0.1 ml of chase medium containing a test agent was added and the plate
was incubated for 30 min; each test agent concentration was evaluated
in triplicate wells. ATP was introduced (from a 100 mM stock solution,
pH 7) to achieve a final concentration of 2 mM, and the plate was
incubated at 37°C for an additional 3 h. Media were harvested
and clarified by centrifugation, and their IL-1
content was
determined by ELISA (R & D Systems; Minneapolis, MN).
Hypotonic Stress-Induced IL-1
Post-Translational
Processing.
Human monocytes were isolated as described above and
used on the day of their isolation. LPS
stimulated/[35S]methionine-labeled cells were
maintained in an isotonic (132 mM NaCl, 0.9 mM
CaCl2, 0.5 mM MgCl2, 2.6 mM
KCl, 1.4 mM KH2PO4, 20 mM
HEPES, pH 7.1, 5 mM glucose, and 1% FBS) or hypotonic (27 mM NaCl, 0.9 mM CaCl2, 0.5 mM MgCl2,
0.53 mM KCl, 0.29 mM
KH2PO4, 20 mM HEPES, pH
7.1, 5 mM glucose, and 1% FBS) medium in the absence or presence of 2 µM CP-412,245. After the indicated incubation times at 37°C, media
and cell-associated samples were harvested separately and processed as
described above.
Preparation of Cytolytic T Lymphocytes (CTLs) and Coculture with
[35S]Methionine-Labeled Macrophages.
Spleens from
C57/Bl mice (Jackson Laboratories, Bar Harbor, MN) were suspended in
RPMI 1640 medium and minced through a metal strainer. The resulting
cell suspension was passed through a filter of sterile Nitex (110 µm;
Tetko Inc., Briarcliff Manor, NY), after which cells were collected by
centrifugation and resuspended in RPMI medium. Spleens from BALB/c mice
(Jackson Laboratories; three spleens in 5 ml of RPMI) were minced
through a metal strainer after dilution with 5 ml of 155 mM ammonium
chloride, 1 mM EDTA, 10 mM potassium bicarbonate, pH 7.2. The resulting
cell suspension was passed through a Nitex filter, cells were collected
by centrifugation, and the cell pellet was suspended in 2 ml of RPMI
1640. This BALB/c spleen cell suspension was irradiated for 23 min at
80 kV and 5 mA. To elicit a mixed lymphocyte response, T-75 flasks were seeded with 2.5 × 106 C57/Bl spleen
cells/ml and 0.5 × 106 irradiated BALB/c
cells/ml; each T-75 flask received 50 ml total volume of RPMI 1640 medium containing 10% fetal bovine serum, 1% nonessential amino
acids, 1% penicillin/streptomycin, 2 mM glutamine, 1 mM sodium
pyruvate, and 0.01 mM
-mercaptoethanol. After 5 days at 37°C in a
5% CO2 environment, cells were harvested by
centrifugation and washed twice with RPMI 1640, 1% FBS, 25 mM HEPES,
pH 7.3. Prior to their addition to macrophage target cells, an
appropriate number of cells from the activated CTL preparation was
collected by centrifugation and suspended in 0.5 ml of RPMI 1640 containing 25 mM HEPES, pH 7.3, 1 µg/ml LPS, 1% FBS, and test agent,
where indicated.
-minimal essential medium containing 1%
dialyzed FBS, 25 mM HEPES, 5 mM NaHCO3, pH 7.3, and 83 µCi/ml [35S]methionine. Pulse media
were removed and the cells were rinsed once with RPMI 1640, 25 mM
HEPES, pH 7.3, 1 µg/ml LPS, and 1% FBS. At this point, 1 ml of the
CTL cell suspension (with or without a test agent) was added to achieve
a ratio of spleen cells to macrophages of 20:1. Cocultures were
incubated at 37°C for 4 h after which cells and media were
harvested separately.
Immunoprecipitation of IL-1
and Analysis of Radiolabeled
Cytokine Product.
IL-1
was immunoprecipitated from detergent
extracts of cell and media samples by addition of 3 µl of a rabbit
anti-human IL-1
serum (Collaborative Research) or 3 µl of goat
anti-mouse IL-1
(Perregaux et al., 1998a
). After a 2-h incubation at
4°C, 0.25 ml of a 10% suspension of Protein A- (human) or Protein
G-Sepharose (mouse) was added and the resulting immune complexes were
recovered by centrifugation. The bead-bound complexes were washed five
times with 10 mM Tris, pH 8, 10 mM EDTA, 1% Triton X-100, 0.4%
deoxycholate, 0.1% SDS and once with 50 mM Tris, pH 6.8. The final
pellets were suspended in 0.1 ml of SDS disaggregation buffer and
boiled for 3 min; beads were removed by centrifugation, and the
disaggregated immunoprecipitate supernatants were stored at
20°C
prior to analysis by SDS gel electrophoresis and autoradiography. Gels
were soaked in Amplify (Amersham Pharmacia Biotech) prior to drying.
Quantitation of the amount of radioactivity associated with the various
species of IL-1
was determined with an Ambis Image Analysis System
(San Diego, CA).
Isolation of Human Monocyte Conditioned Medium and Hepatocyte Bioassay. Mononuclear cells isolated from heparinized blood obtained from an individual normal volunteer were seeded into tissue culture dishes and maintained in macrophage serum-free medium (SFM; Invitrogen, Carlsbad, CA). After a 2-h incubation, nonadherent cells were removed, the attached monocytes were rinsed twice with SFM, and the cultures were incubated overnight in SFM containing 100 ng/ml recombinant human macrophage colony-stimulating factor (R & D Systems). This medium subsequently was discarded and replaced with RPMI 1640 medium containing 1% FBS, 25 mM HEPES, pH 6.9, and 10 ng/ml LPS, and the cultures were incubated for 3 h at 37°C. In some cases, CP-424,174 was added to the culture medium at the time of LPS addition, but in others the test agent was coadministered with the ATP secretion stimulus. CP-424,174 was introduced from a dimethyl sulfoxide stock solution to achieve the desired final concentration; in all cases, the final dimethyl sulfoxide vehicle concentration was 0.2% and the control cultures received vehicle alone. ATP (from a 100 mM stock solution previously adjusted to pH 7) was introduced to achieve a 2 mM final concentration, and the cultures were incubated for an additional 3 h. Conditioned media subsequently were harvested and clarified by centrifugation.
The Hep3B bioassay was performed as detailed previously (Laliberte et al., 1997
, 10 ng/ml (Collaborative Research); and IL-1RA, 10 µg/ml (R & D Systems).
Hepatoma cell cultures were stimulated for 20 h after which the
activation media were removed and the cells were incubated in 1 ml of
methionine-free RPMI 1640 medium containing 1%
penicillin/streptomycin, 20 mM HEPES, pH 7.3, 1 µM dexamethasone,
0.1% Redu Serum, and 160 µCi of
[35S]methionine. After a 60-min incubation at
37°C, the pulse-medium was discarded, the cell monolayers were rinsed
to remove free [35S]methionine, and the cells
were solubilized by detergent extraction. Cell extracts were clarified
by centrifugation, and serum amyloid A was recovered from the resulting
supernatants by immunoprecipitation; a sheep antiserum was obtained
from Calbiochem (San Diego, CA). Resulting immunoprecipitates were
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) (15%
polyacrylamide) and autoradiography.
In Vivo LPS/ATP Challenge Assay.
Male Swiss-Webster mice, 6 to 10 weeks of age, were obtained from Taconic Farms (Germantown, NY).
Mice were maintained for 1 week before use in a temperature-controlled
room with a 12-h light/dark cycle and were allowed free access to
standard laboratory chow and water. All procedures were approved by the
Institutional Animal Care and Use Committee. Mice were injected with 1 µg of LPS (E. coli 055:B5; Sigma) in 0.5 ml of PBS. Sixty
minutes later, the mice were dosed with test agent (as a 0.5%
suspension in methyl cellulose) or vehicle by gavage, followed 60 min
later by an i.p. injection of ATP (0.5 ml of a 30 mM solution in PBS
neutralized to pH 7.3 with NaOH). After an additional 15-min
incubation, the mice were euthanized by cervical dislocation, and the
peritoneal cavity was lavaged with 3 ml of ice-cold PBS containing 10 U/ml heparin sodium salt (ICN Biochemicals, Cleveland, OH), 0.25 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 mM EDTA.
Samples were maintained on ice prior to clarification by
centrifugation; the resulting supernatants were harvested and stored at
20°C. ELISA kits for the measurement of murine cytokines were
obtained from Genzyme (Cambridge, MA; IL-1
) and Endogen (Boston, MA;
IL-1
, IL-6, and TNF
).
Other Procedures. Trichloroacetic acid (TCA) precipitation analysis was performed by spotting duplicate aliquots of media samples and cell extracts onto 1-cm glass fiber filter circles. One of these filters was air-dried to yield the total radioactivity. The duplicate filters were placed into individual wells of six-well cluster plates containing 2 ml of cold 5% TCA and incubated for 30 min at 4°C with gentle agitation. Solutions were removed by aspiration and the filters were washed twice with 2 ml of 5% TCA, twice with 95% ethanol, and once with absolute ethanol (all at 4°C, 30 min/wash). These filters then were air-dried, after which all filters were placed into 4 ml of scintillation fluid for radioactivity counting. The difference in the quantity of radioactivity recovered from the filters with and without TCA precipitation is attributed to TCA-soluble components. Aliquots of media samples and cell extracts were assessed for lactate dehydrogenase (LDH) content by using pyruvate as substrate and a colorometric pyruvate detection assay (Sigma).
| |
Results |
|---|
|
|
|---|
Identification of Diarylsulfonylureas as Inhibitors of IL-1
Post-Translational Processing.
Based on evidence obtained in
previous studies indicating that ionic changes facilitate IL-1
post-translational processing (Perregaux and Gabel, 1994
; Walev et al.,
1995
; Perregaux et al., 1996
), a number of pharmacological agents known
to block ion channel and/or ion transport activity were assessed as
inhibitors of human monocyte stimulus-coupled IL-1
post-translational processing. This assessment was performed in a
two-step assay: blood-derived monocytes were activated with LPS to
promote synthesis of pro-IL-1
after which they were treated with ATP
to initiate cytokine post-translational processing in the absence or
presence of a test agent. Concentrations of IL-1
within media
recovered from these cultures then were determined by ELISA. Most
agents tested were inactive but glyburide, a sulfonylurea-containing
drug that is known to inhibit ATP-activated K+
channels found in pancreatic
-cells (Ashcroft and Ashcroft, 1992
),
blocked IL-1
production in a dose-dependent manner (Fig. 1); the IC50 for
this agent was determined to be 12 µM (±5 µM; n = 23). In contrast, the closely related sulfonylurea glipizide did not
produce significant inhibition of ATP-induced IL-1
post-translational processing at concentrations
100 µM (Fig. 1).
This selectivity led us to characterize a number of structurally
related analogs in an attempt to find agents more potent than
glyburide. A class of compounds designated as diarylsulfonylureas
demonstrated improved activity in the cytokine production assay, and
examples of two such compounds are shown in Fig.
2. These two agents, CP-424,174 and
CP-412,245, blocked ATP-induced IL-1
post-translational processing with IC50 values of 0.21 µM (±0.06 µM;
n = 20) and 0.26 µM (±0.05 µM; n = 4), respectively (Fig. 1). Not all diarylsulfonylureas were effective
cytokine release inhibitors; the anticancer compound sulofenur (Talbot
et al., 1993
), for example, produced only modest inhibition when tested
at concentrations
50 µM (Fig. 1).
|
|
, SKF86002, is
reported to block the low spontaneous release of IL-1
from human
monocytes challenged with LPS only (Chin and Kostura, 1993
post-translational processing (data
not shown), suggesting that diarylsulfonylureas disrupt a mechanism
distinct from that affected by the stress kinase inhibitor.
Demonstration of IL-1
Post-Translational Processing Inhibition
in a Metabolic Assay Format.
To confirm CRID activity,
LPS-activated/[35S]methionine-labeled human
monocytes were treated with ATP in the absence and presence of
CP-424,174. IL-1
subsequently was recovered by immunoprecipitation from the media and cell-associated fractions, and the
immunoprecipitates were analyzed by SDS-PAGE and autoradiography.
ATP-treated cultures yielded large quantities of extracellular mature
17-kDa IL-1
and smaller quantities of 31-kDa pro-IL-1
(Fig.
3B). In contrast, cell-associated
cytokine recovered from ATP-treated cells consisted almost exclusively
of the procytokine (Fig. 3A). Addition of CP-424,174 to the medium led
to loss of extracellular 17-kDa mature IL-1
(Fig. 3B). At 100 nM,
little inhibition was observed, but 500 nM and 2.5 µM CP-424,174
inhibited production of the 17-kDa species nearly completely (Fig. 3C).
Importantly, this decrease in the levels of extracellular 17-kDa
cytokine was not compensated by an increase in the quantity of the
31-kDa species released (Fig. 3B), nor by an appearance of the 17-kDa
species intracellularly (Fig. 3A). CP-424,174, therefore, inhibited
both the post-translational proteolytic maturation of pro-IL-1
and
the release of all cytokine species. ATP also promotes release of
IL-1
from LPS-primed peritoneal macrophages (Perregaux and Gabel,
1998a
), and externalization of this form of IL-1 was sensitive to
inhibition by CP-424,174 (data not shown).
|
extracellularly as did
cells that were not exposed to the test agent (Fig. 3, B and C).
Addition of CP-424,174 to the monocyte cultures 15 min after initiation
of the ATP response resulted in 60% inhibition of mature IL-1
production (Fig. 3, B and C).
Similar inhibitory effects were observed with CP-412,245.
LPS-activated/[35S]methionine-labeled monocytes
exposed to ATP in the presence of this agent produced less 17-kDa
mature IL-1
than did control ATP-treated cultures (Fig.
4A). At 250 nM, this agent produced 44%
inhibition, and concentrations
1 µM inhibited mature cytokine formation >95% (Fig. 4B). The cytokine release inhibitory effect again was reversible, and monocytes that were pretreated with 4 µM
CP-412,245 for 15 min and then exposed to ATP in its absence generated
levels of 17-kDa IL-1
comparable with those produced by the control
cells (Fig. 4A). Addition of CP-412,245 to the monocyte cultures 15 min
after ATP resulted in 50% inhibition in mature cytokine production
(Fig. 4, A and B).
|
Diarylsulfonylureas Prevent Murine Peritoneal Macrophage IL-1
Post-Translational Processing in Response to Allogeneic CTL
Challenge.
LPS-activated murine peritoneal macrophages release
mature IL-1
when challenged with allogeneic CTLs in vitro (Hogquist
et al., 1991b
). To determine whether IL-1
post-translational
processing induced by this type of cellular stimulus was
CRID-sensitive, LPS-activated/[35S]methionine-labeled BALB/c
peritoneal macrophages were cocultured with an effector CTL preparation
(derived from C57 mice previously sensitized to irradiated BALB/c
spleen cells in a mixed lymphocyte reaction) in the absence and
presence of CP-424,174. In the absence of CTLs, radiolabeled
macrophages released no cytokine extracellularly (Fig.
5). Addition of CTLs promoted formation
and release of 17-kDa IL-1
(Fig. 5A); >80% of the radiolabeled
IL-1
recovered after 3 h of coculture was recovered
extracellularly as the 17-kDa species. When CP-424,174 was added to the
cocultures, on the other hand, a concentration-dependent decrease in
17-kDa cytokine formation was observed (Fig. 5). CP-424,174 (1 µM)
inhibited CTL-induced post-translational processing by 86%, with less
inhibition observed at lower concentrations (Fig. 5B).
CP-424,174-treated macrophages did not accumulate 17-kDa mature
cytokine intracellularly (data not shown).
|
CP-424,174 Prevents Human Monocyte IL-1
Post-Translational
Processing in Response to Hypotonic Stress.
Hypotonic stress is an
effective stimulus for promoting IL-1
post-translational processing
from human monocytes (Walev et al., 1995
; Perregaux et al., 1996
), and
CRIDs also impaired this type of stimulus-coupled processing.
LPS-activated/[35S]methionine-labeled monocytes
subjected to hypotonic stress in the absence of CP-412,245 demonstrated
a time-dependent release of mature 17-kDa IL-1
. After just 15 min of
hypotonic exposure, 17-kDa IL-1
was detected extracellularly, and
quantities of this species increased after 30 and 60 min of treatment.
Extending the treatment time to 120 and 180 min produced little
additional mature cytokine (Fig. 6).
Based on recovery of total radiolabeled IL-1
from these cultures
(sum of both intracellular and extracellular species and corrected for
the 2-fold loss of [35S]methionine as a result
of caspase-1 cleavage), >80% was accounted for by the extracellular
17-kDa species after 60 min of treatment. Addition of CP-412,245 to the
hypotonic medium effectively inhibited cytokine post-translational
processing (Fig. 6A), and quantities of extracellular 17-kDa IL-1
recovered in the presence of this agent were minimal throughout the
entire 3-h observation period (Fig. 6B). Additionally,
CP-412,245-treated monocytes did not release pro-IL-1
(Fig. 6A).
Hypotonic stress also promoted release of LDH; the time course for
release of the cytoplasmic marker correlated with release of mature
17-kDa IL-1
(Fig. 6B). In the presence of CP-412,245, release of LDH
was greatly attenuated (Fig. 6B).
|
|
. After 180 min of
hypotonic exposure many, but not all, monocytes possessed a swollen
appearance (Fig. 8B). The morphology of monocytes maintained for 3 h in an isotonic medium, on the other hand, was similar to that
displayed by cells at the beginning of the treatment (Fig. 8, A and D).
Cultures exposed to the hypotonic medium in the presence of 2 µM
CP-412,245 contained few swollen cells but evidence of cytoplasmic
clearing was apparent in some cells (Fig. 8C).
|
Conditioned Medium Derived from CP-424,174-Treated Monocytes
Demonstrates Diminished Signaling Capacity.
Conditioned medium
harvested from human monocytes treated with LPS is a rich source of
many cytokine products, including IL-1 (McNiff et al., 1995
). To assess
selectivity of the CRID effect, human monocytes were activated with LPS
after which they were treated with ATP in the absence and presence of
CP-424,174 and levels of three different cytokine products, IL-1
,
IL-6, and the natural receptor antagonist of IL-1, IL-1RA (Arend et
al., 1998
), released to the medium were determined by ELISA. We
demonstrated previously that the amount of IL-1
released into
monocyte conditioned medium was greatly enhanced in the presence of
ATP, whereas levels of IL-6 and IL-1RA were not significantly affected
by the nucleotide triphosphate (Laliberte et al., 1997
). Conditioned
medium prepared in the absence and presence of CP-424,174 contained
comparable quantities of IL-6 and IL-1RA (Table
1, experiment 1). IL-6 was present at 26 ng/ml in the absence of CP-424,174 and at 19 ng/ml in its presence;
therefore, a 1.4-fold reduction occurred in the presence of the test
agent. Likewise, IL-1RA levels were 128 and 137 ng/ml in the absence
and presence of CP-424,174, respectively. In contrast, the quantity of
IL-1
was reduced 30-fold in the presence of CP-424,174 (Table 1,
experiment 1). In a second experiment, CP-424,174 was introduced to the
cultures simultaneously with LPS and maintained throughout the entire
LPS and ATP treatment arms. Relative to control cultures, CP-424,174
caused a concentration-dependent inhibition of IL-1
production and
achieved a maximal suppression of >99% (Table 1, experiment 2). In
contrast, CP-424,174 produced only modest reductions in the secreted
levels of IL-1RA and TNF
(Table 1, experiment 2); the latter
cytokine is produced as a membrane-anchored precursor in the
endoplasmic reticulum and is subsequently released by proteolysis to
the medium. CP-424,174 reduced production of IL-6 by less than 2-fold
(Table 1, experiment 2). Thus, CP-424,174 selectively impaired
production of IL-1
by LPS-activated/ATP-treated monocytes.
|
was biologically
significant, the signaling capacity of the monocyte conditioned media
prepared in the absence and presence of CP-42,4174 was compared. For
this purpose, a bioassay was used; Hep3B cells produce the acute phase
protein SAA in response to stimulation by monocyte conditioned medium
(McNiff et al., 1995
|
Oral Administration of CP-424,174 to Mice Selectively Blocks IL-1
Production.
LPS priming of peritoneal cells in vivo generates
small quantities of extracellular IL-1, and these quantities are
greatly enhanced when ATP is injected into the peritoneal cavity
(Griffiths et al., 1995
). This system was used to determine whether
CP-424,174 could inhibit IL-1 production in vivo. After oral
administration, CP-424,174 inhibited ATP-induced IL-1
and IL-1
release from LPS-primed peritoneal cells (Fig.
10A); the ED50
for inhibition of both cytokines was similar (15 ± 3 mg/kg for
IL-1
and 14 ± 3 mg/kg for IL-1
). Importantly, as observed
in vitro, inhibition of IL-1 production in vivo is a selective process.
Mice treated with CP-424,174 produced levels of IL-6 and TNF
that
were comparable with those generated by vehicle-treated animals (Fig.
10B). CP-424,174, therefore, is orally bioavailable in mice and capable
of achieving levels at peripheral locations sufficient for the
selective inhibition of stimulus-coupled IL-1 production.
|
| |
Discussion |
|---|
|
|
|---|
A limited number of potential therapeutic approaches have been
proposed to regulate IL-1 activity and all have limitations. For
example, recombinant IL-1RA, either as the protein or via its
transgenic expression, has demonstrated anti-inflammatory activity in
both animal models and human clinical trials (Arend et al., 1998
;
Bresnihan et al., 1998
; Bendele et al., 1999
). The relatively short in
vivo half-life of the recombinant protein, however, necessitates that
large quantities of the recombinant polypeptide be generated and/or
used. Likewise, caspase-1 inhibitors have demonstrated efficacy in
animal models of inflammatory diseases (Miller et al., 1995
; Ku et al.,
1996
), and mice engineered to lack this enzyme display reduced
inflammatory processes (Kuida et al., 1995
; Li et al., 1995
). Caspase-1
inhibitors, however, are not expected to directly affect production of
IL-1
, and pro-IL-1
released in their presence may be processed by
extracellular proteases to an active cytokine species (Hazuda et al.,
1990
). Peptide-based antagonists of IL-1 receptors also have been
generated, and these can inhibit IL-1 signaling processes (Akeson et
al., 1996
). The peptidic nature of these antagonists carries metabolic
liabilities that limit their in vivo utility. Finally, a number of
nonselective inhibitors of anion transport (e.g., tenidap, ethacrynic
acid, meclofenamic acid) have been shown to inhibit stimulus-coupled IL-1 production in vitro (Laliberte et al., 1994
). Multiple other activities associated with the aforementioned anion transport inhibitors and their low potency, however, make them poor candidates as
CRIDs. Nonetheless, activity of these latter agents is consistent with
previous observations demonstrating that stimulus-coupled IL-1
processing requires changes to the ionic status of the cell, and agents
that promote IL-1 post-translational processing share an ability to
alter ionic homeostasis. For example, ATP ligation of the
P2X7 receptor leads to membrane depolarization
and efflux of intracellular K+ (Sung et al.,
1985
). Increasing extracellular K+ inhibits
ATP-induced IL-1
processing by human monocytes presumably by
preventing cytoplasmic depletion of this cation (Perregaux and Gabel,
1994
; Walev et al., 1995
). In addition, extracellular Na+ is required for post-translational processing
of IL-1
(Perregaux and Gabel, 1998b
), and an important role for
anions in the cellular process is suggested by the finding that
replacement of extracellular Cl
with chaotropic
anions (e.g., iodide or nitrate) blocks stimulus-coupled processing
(Perregaux et al., 1996
).
The ionic dependence of the stimulus-coupled response prompted us to
screen a panel of known ion transport inhibitors for their ability to
alter IL-1 production. Although most inhibitors evaluated were without
effect, the sulfonylurea glyburide blocked IL-1
post-translational
processing in a dose-dependent manner. This effect is considered
selective because similar concentrations of the structurally related
drug glipizide did not inhibit cytokine production. Concentrations of
glyburide required to inhibit the monocyte response are in great excess
of those required to bind to the high-affinity sulfonylurea receptor
associated with the pancreatic
-cell ATP-gated
K+ channel (Ashcroft and Ashcroft, 1992
). This
difference in potency, combined with the discordance between the shared
ability of both glyburide and glipizide to bind to the
-cell
sulfonylurea receptor but only glyburide blocks the monocyte response,
indicates that glyburide's inhibitory effect is not due to inhibition
of an ATP-gated K+ channel. Glyburide also is
known to inhibit several types of anion transporters, including CFTR at
concentrations >1 µM (Sheppard and Welsh, 1992
). Luciani et al.
(1997)
independently discovered that glyburide blocked IL-1
post-translational processing, and suggested that this effect was
dependent on inhibition of a P-glycoprotein type of transporter, ABC-1
(Luciani et al., 1997
). The actual molecular target of glyburide within
monocytes remains to be established.
A search for structurally related compounds that were more potent than
glyburide led to the discovery of diarylsulfonylureas CP-424,174 and
CP-412,245. These agents act as reversible, selective inhibitors of
stimulus-coupled post-translational processing; they do not inhibit
production of cytokines such as IL-6, TNF
, and IL-1RA whose export
is not dependent on a secretory stimulus. Cytokine products such as
these rely on the constitutive secretory pathway involving the
endoplasmic reticulum and Golgi apparatus and they do not accumulate
within the cell. Importantly, CRIDs block IL-1 post-translational
processing initiated by ATP, cytolytic T cells, and hypotonic stress,
indicating that they interfere with a step common to all initiators of
the cytokine post-translational response. Diarylsulfonylurea-arrested
cells were impaired in several aspects of the IL-1 post-translational
response; these agents block formation and release of mature 17-kDa
IL-1
, and this blockade occurs without a compensatory increase in
the quantity of pro-IL-1
recovered extracellularly, as is observed
with some caspase-1 inhibitors (Thornberry et al., 1992
). Lack of
17-kDa IL-1
formation suggests that caspase-1 is not activated in
the presence of diarylsulfonylureas; recombinant caspase-1 activity,
however, is not affected by these agents when tested in a cell-free
assay (data not shown). Diarylsulfonylureas block IL-1
post-translational processing even when added 15 min after ATP;
previous studies demonstrated that chloride removal from the medium
during this same time period blocked the cellular response (Perregaux
et al., 1996
). This correspondence raises the possibility that CRIDs
alter cytokine processing by affecting a chloride-dependent step, but
their precise mode of action remains to be established.
The diarylsulfonylureas also block release of LDH and TCA-precipitable
macromolecules from stimulus-activated monocytes. Release of these
cellular components is probably the result of damage to the plasma
membrane driven, in part, by an extensive increase in cell volume
(Perregaux et al., 1996
). This volume change appears to be an important
component of the stimulus-coupled cytokine response; for example,
monocytes treated with ATP in a hypertonic medium did not release
mature IL-1
and they did not demonstrate the marked increase in cell
volume (Perregaux et al., 1996
). Remarkably, CP-412,245 blocks the cell
volume increase as evidenced by its ability to reduce the number of
swollen cells after hypotonic stress. Therefore, CRIDs appear to arrest
monocytes/macrophages at an early step in the activation process that
preserves cell membrane integrity. The ultimate fate of pro-IL-1
that is retained within the arrested cells and the long-term viability
of the cells themselves remain to be determined.
Is an agent that inhibits IL-1 post-translational processing likely to
suppress IL-1-dependent signaling processes? We demonstrated previously
that the complex mixture of cytokines generated by LPS-activated human
monocytes is more effective as an inducer of the acute phase protein
SAA when prepared in the presence of ATP (Laliberte et al., 1997
).
Inclusion of the nucleotide triphosphate caused a large shift in the
ratio of IL-1
to IL-1RA, resulting in an enhanced IL-1 signaling
capacity as measured by the ability of the conditioned medium to
promote hepatoma cell SAA synthesis. In contrast, in the absence of ATP
the balance of IL-1 to IL-1RA within the conditioned medium favored the
antagonist and little SAA synthesis was induced. A large excess of
IL-1RA over IL-1 is required to impair the cytokine's signaling
activity (Arend et al., 1998
), and treatments that shift the agonist
concentration in the presence of a fixed amount of antagonist are
expected to alter signaling capacity. Indeed, conditioned medium
derived from LPS-activated/ATP-treated monocytes maintained in the
presence of CP-424,174 demonstrated a markedly reduced ability to
promote SAA synthesis by hepatoma cells relative to medium prepared in the absence of this agent. The reduction in signaling capacity was not
accompanied by a decrease in the quantities of IL-6 and/or IL-1RA, but
was associated with a large decrease in IL-1
levels. Therefore, by
reducing the ratio of IL-1
to IL-1RA, CP-424,174 suppressed the
signaling capacity of monocyte conditioned medium with respect to an
IL-1-dependent process. Stimulus-coupled IL-1 post-translational
processing also has been demonstrated in vivo; LPS activated murine
peritoneal macrophages generate minimal quantities of extracellular
IL-1
in the absence of a secretion stimulus, and the subsequent
injection of ATP evokes large quantities of mature cytokine (Griffiths
et al., 1995
). A stimulus-coupled response mechanism thus appears to be
required for efficient production of extracellular IL-1 in vivo as well
as in vitro. CP-424,174 impaired stimulus-coupled IL-1
and IL-1
production after oral administration to mice without affecting
production of the LPS-inducible cytokines IL-6 and TNF
. Therefore,
CRID-like agents are expected to dampen IL-1-dependent signaling events
and to provide therapeutic utility to patients suffering from diseases
such as rheumatoid arthritis where IL-1 is thought to serve as a major
mediator of the inflammatory process.
| |
Footnotes |
|---|
Accepted for publication June 26, 2001.
Received for publication April 4, 2001.
Address correspondence to: C. A. Gabel, Inflammation Department, PGRD, Pfizer, Inc., Groton, CT. E-mail: christopher_a_gabel{at}groton.pfizer.com
| |
Abbreviations |
|---|
IL, interleukin; LPS, lipopolysaccharide; CRID, cytokine release inhibitory drug; FBS, fetal bovine serum; ELISA, enzyme-linked immunosorbent assay; PMSF, phenylmethylsulfonyl fluoride; CTL, cytotoxic T lymphocyte; SFM, serum-free medium; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; TCA, trichloroacetic acid; LDH, lactate dehydrogenase; SAA, serum amyloid A.
| |
References |
|---|
|
|
|---|
-converting enzyme is present in monocytic cells as an inactive 45 kDa precursor.
J Immunol
153:
2592-2599[Abstract].
precursor.
J Biol Chem
266:
12162-12167
converting enzyme.
Science (Wash DC)
256:
97-100
synthesis and secretion in human blood monocytes stimulated with bacterial cell wall products.
J Immunol
151:
5574-5585[Abstract].
and inflammatory disease.
J Biol Chem
265:
6318-6322
converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice.
Cytokine
8:
377-386[Medline].
converting enzyme.
Science (Wash DC)
267:
2000-2002
posttranslational processing is a dynamic process dependent on in vitro growth conditions.
J Leukoc Biol
62:
227-239[Abstract].
-converting enzyme are defective in production of mature IL-1
and resistant to endotoxic shock.
Cell
80:
401-411[Medline].
secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1.
Blood
90:
2911-2915
and IL-6 to promote production of serum amyloid A by Hep3B cells.
Cytokine
7:
209-219[Medline].
production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1
converting enzyme.
J Immunol
154:
1331-1338[Abstract].
-converting enzyme expression: only precursor forms are detected in interleukin-1
-secreting cells.
Eur J Immunol
26:
1032-1042[Medline].
precursor but not the interleukin-1
precursor.
J Biol Chem
262:
2941-2944
maturation and release in response to ATP and nigericin.
J Biol Chem
269:
15195-15203
and IL-1
occurs via a similar mechanism.
J Immunol
160:
2469-2477
posttranslational processing: modulation via monovalent cations.
Am J Physiol
275:
C1538-C1547
posttranslational processing. Evidence of a volume regulated response.
J Biol Chem
271:
29830-29838
, a protein lacking a signal sequence.
EMBO (Eur Mol Biol Organ) J
9:
1503-1510[Medline].
processing in monocytes.
Nature (Lond)
356:
768-774[Medline].
in human monocytes.
EMBO (Eur Mol Biol Organ) J
14:
1607-1614[Medline].
inducing factor mediated by interleukin-1
converting enzyme.
Science (Wash DC)
275:
206-209This article has been cited by other articles:
![]() |
R. E. Laliberte, D. G. Perregaux, L. R. Hoth, P. J. Rosner, C. K. Jordan, K. M. Peese, James. F. Eggler, M. A. Dombroski, K. F. Geoghegan, and C. A. Gabel Glutathione S-Transferase Omega 1-1 Is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interleukin-1beta Posttranslational Processing J. Biol. Chem., May 2, 2003; 278(19): 16567 - 16578. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Perregaux, K. Bhavsar, L. Contillo, J. Shi, and C. A. Gabel Antimicrobial Peptides Initiate IL-1{beta} Posttranslational Processing: A Novel Role Beyond Innate Immunity J. Immunol., March 15, 2002; 168(6): 3024 - 3032. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||